Retatrutide (60 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Retatrutide (research code LY3437943) is a single-molecule triple agonist studied for its activity at the GLP-1, GIP and glucagon receptors. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 60 mg vial, adding 6.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). That is the same working concentration used for smaller fills, so the per-injection unit and volume math stays identical — every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg of material. The difference with a 60 mg fill is purely capacity: a single reconstituted vial holds six times the material of a 10 mg vial, which keeps freeze-thaw handling to a minimum but means the 6.0 mL of diluent must be split across one or two stoppered transfers, since a 60 mg lyophilized cake is typically supplied in a vial with limited headroom.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation arms used in the Phase 2 program, where weekly amounts were stepped up roughly every four weeks to manage gastrointestinal tolerability. Per-injection amounts are unchanged from the source research range — only the "vials per dose" column changes for the larger fill, because no single weekly dose comes close to exhausting a 60 mg vial.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw the bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet. Because a 60 mg cake needs 6.0 mL of diluent, add it in two 3.0 mL transfers if the vial lacks headroom for the full volume at once, venting briefly between transfers.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time. Given the large number of draws a 60 mg vial supports, consider aliquoting into smaller sterile vials to limit stopper punctures.

Advanced (Aggressive) Titration Schedule

The advanced schedule reaches the 12 mg ceiling tested in Phase 2, where the highest cohort recorded the largest average weight reductions. It escalates faster, but even at the 12 mg top step a single 60 mg vial comfortably covers the full weekly volume — no second vial is required per dose at this fill size.

Supplies Needed

• Retatrutide vials (60 mg): ~1 vial for a 12-week gradual run to 6 mg; ~3 vials for a 24-week run to 8 mg; ~1 vial for a 12-week aggressive run to 8 mg.
• Insulin syringes (U-100, 1 mL): 12–24 for a 12-week schedule; 24–48 for 24 weeks (one fresh syringe per draw; allow a second syringe per dose at the 12 mg step).
• Bacteriostatic water (10 mL): one bottle reconstitutes a single 60 mg vial with margin; two bottles for a 3-vial, 24-week run.
• Alcohol swabs: a single 100-count box covers a 12–24 week schedule.
• Sterile empty vials (optional): 2–3 for aliquoting a reconstituted 60 mg fill to reduce repeated stopper entry.

Protocol Overview

• Research goal: model metabolic weight-regulation via simultaneous GLP-1, GIP and glucagon receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2–8 mg standard, up to 12 mg in aggressive arms.
• Fill: 60 mg lyophilized, reconstituted to 10 mg/mL with 6 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 2 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Target the mid-band (6–8 mg) for the bulk of the published efficacy signal.
• Because a single 60 mg vial spans many weeks of dosing, track the reconstitution date carefully — the 4-week post-reconstitution window, not the lyophilized shelf life, governs how long the solution remains usable.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (−4 °F) or colder, protected from light and moisture, where stability extends to roughly 24 months. Once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and use within about four weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and — given how many draws a 60 mg fill supports — aliquoting into smaller sterile vials is the preferred way to limit stopper damage and contamination risk.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact across the vial's long working life.
• Split larger volumes (the 12 mg / 1.20 mL step) across two draws when they exceed a single syringe's capacity.
• Document each draw — date, volume, remaining material — for reproducibility, which matters more on a high-capacity 60 mg vial.

How Retatrutide Works

Retatrutide is a synthetic peptide engineered to act as a balanced agonist at three incretin and metabolic receptors at once: GLP-1 and GIP (both involved in glucose-dependent insulin signalling and appetite suppression) and the glucagon receptor (linked to raised metabolic rate, energy expenditure and hepatic lipid handling). Activating GLP-1 and GIP enhances insulin secretion and curbs intake, while the glucagon-receptor component pushes energy expenditure and lipid oxidation upward — the combination is what drives the potent fat-loss and glycemic signals seen in trials. A fatty-acid moiety extends its half-life to about six days, which is what supports the once-weekly dosing cadence and distinguishes it from single (GLP-1) and dual (GLP-1/GIP) agonists in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in trials

• Average body-weight reduction of roughly 22–24% at 48 weeks in the highest-dose (8–12 mg) obesity cohort.
• HbA1c reductions of about 1.3–2.0% in the Type 2 diabetes study (from ~8.0% toward ~6.0%), with roughly 82% reaching HbA1c ≤6.5%.
• Improvements in blood pressure, LDL cholesterol, waist circumference and liver-fat markers, including resolution of hepatic steatosis in over 80% of evaluated participants.
• Every participant in the 8–12 mg arms achieved at least 5% weight reduction.

Side effects reported

• Dose-dependent gastrointestinal effects — mild-to-moderate nausea, vomiting and diarrhoea — most common during escalation.
• Generally transient and meaningfully reduced by slower titration on the four-week-interval schedule.
• No severe hypoglycaemia or serious treatment-related adverse events were reported in the Phase 2 program.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the published study designs.
• Combined resistance training (2–3×/week) and regular aerobic activity to preserve lean mass.
• Adequate sleep (7–9 hours) and stress management as standard trial-adherence controls.
• Maintained hydration, with monitoring for dehydration during GI side effects.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work. Inject slowly and steadily.
• For volumes above ~1.0 mL (the 12 mg step), split into two injections at separate sites — for example left and right abdomen.
• Rotate sites systematically (abdomen preferred, also thighs and upper arms) to avoid lipohypertrophy, then dispose of sharps in an approved container.

References

Related Protocols